Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Pharma thinks it's found the next frontier in preventing heart attacks. Novartis , Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a) can protect people from heart attacks. …